<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Leukemia vaccine passes key trial, adding to breakthrough year for cancer drugs — Live Feed</title><link>https://www.live-feeds.com/feed/leukemia-vaccine-passes-key-trial-adding-to-breakthrough-year-for-cancer-drugs</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/leukemia-vaccine-passes-key-trial-adding-to-breakthrough-year-for-cancer-drugs/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>Leukaemia Vaccine Passes Key Trial</title><link>https://www.live-feeds.com/feed/leukemia-vaccine-passes-key-trial-adding-to-breakthrough-year-for-cancer-drugs</link><guid isPermaLink="false">https://www.live-feeds.com/feed/leukemia-vaccine-passes-key-trial-adding-to-breakthrough-year-for-cancer-drugs#u213456</guid><pubDate>Sun, 22 Nov 2026 13:52:33 +0000</pubDate><description>An experimental blood cancer immunotherapy developed by Sellas Life Sciences has successfully passed a key clinical trial, marking a significant milestone in a strong year for cancer drugs. The vaccine extended survival in patients with acute myeloid leukaemia, demonstrating a survival benefit of nine months in a late-stage study. Following the positive data, company shares surged and tripled in value. The treatment also reduced the overall risk of death in the clinical trial, adding strong momentum to the biotechnology sector and placing the developer among top industry performers.Why it matt</description></item>
</channel></rss>